Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04545060 · ClinicalTrials.gov registry record · Phase 2
VIR-7831 for the Early Treatment of COVID-19 in Outpatients
A Phase 2 study, sponsored by Vir Biotechnology.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,057
- Enrollment target
NCT04545060 is a Phase 2 study that has completed, run by Vir Biotechnology. The registered enrollment target is 1,057 participants.
The verdict
NCT04545060, a Phase 2 study, has completed, sponsored by Vir Biotechnology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,057 participants
- Enrollment target
Study Summary
This is a phase 2/3 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 or placebo and will be assessed for safety, tolerability, efficacy, and pharmacokinetics.
Interventions
- DRUG Placebo
- BIOLOGICAL VIR-7831 (sotrovimab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,057 participants |
| Start Date | 2020-08-27 |
| Est. Completion | 2021-09-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04545060
The ClinicalTrials.gov registry entry for NCT04545060 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,057 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vir Biotechnology, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04545060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04545060 about?
NCT04545060 is a clinical study titled "VIR-7831 for the Early Treatment of COVID-19 in Outpatients". This is a phase 2/3 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 or placebo and will be assessed for safety, tolerability, efficacy, and pharmacokinetics.
What is the current status of trial NCT04545060?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,057 participants. The study started on 2020-08-27. Estimated completion is 2021-09-02.
What interventions are being tested in trial NCT04545060?
The interventions under investigation include: Placebo (DRUG), VIR-7831 (sotrovimab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04545060?
This trial is sponsored by Vir Biotechnology, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.